ALISO VIEJO, Calif., Jan. 8, 2024 /PRNewswire/ -- Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced the appointment of Rhonda Robb as President and Chief Executive Officer..

加利福尼亚州ALISO VIEJO，2024年1月8日/PRNewswire/--Okami Medical Inc.，一家专注于开发创新解决方案的医疗器械公司，今天宣布任命Rhonda Robb为总裁兼首席执行官。。

Rhonda is a proven medical device executive with more than 25 years of leadership and commercial experience. She most recently served as Chief Operating Officer at Cardiovascular Systems, Inc., a leader in the treatment of peripheral and coronary artery disease. Prior to Cardiovascular Systems, Rhonda served as the Vice President and General Manager for Heart Valve Therapies at Medtronic, where she led the transcatheter and surgical heart valve franchises.

朗达是一位久经考验的医疗器械高管，拥有25年以上的领导和商业经验。她最近担任心血管系统公司（Cardiovascular Systems，Inc.）的首席运营官，该公司是治疗外周和冠状动脉疾病的领导者。在加入心血管系统之前，朗达曾担任美敦力心脏瓣膜治疗公司的副总裁兼总经理，负责经导管和外科心脏瓣膜的特许经营。

She also serves on the Board of Directors for 4C Medical..

她还担任4C Medical的董事会成员。。

'Rhonda brings a proven track record and a wealth of experience to the company,' said Bob Rosenbluth, PhD, Co-Founder and Chairman of the Board of Okami Medical. 'She shares our commitment and passion for providing patients and physicians with access to advanced technologies that address the numerous challenges in peripheral vascular occlusion.

Okami Medical联合创始人兼董事会主席鲍勃·罗森布卢斯（BobRosenbluth）博士说，朗达（Rhonda）为公司带来了良好的业绩记录和丰富的经验她与我们一样致力于为患者和医生提供先进技术，以应对外周血管闭塞的众多挑战。

We are thrilled to have her leading the company into the next phase of expansion and growth.'.

我们很高兴她带领公司进入下一个扩张和增长阶段。”。

'I am honored to have the opportunity to lead Okami Medical at this exciting time as we prepare to commercialize our LOBO Vascular Occlusion System,' said Rhonda. 'The team has done a tremendous job of taking the system from the conceptual stage through clinical validation. LOBO is a next-generation technology that is delivering remarkable clinical performance and is uniquely suited to transform and expand the treatment of patients suffering from peripheral vascular conditions.'.

朗达说：“我很荣幸有机会在这个激动人心的时刻领导Okami Medical，因为我们准备将我们的LOBO血管闭塞系统商业化。”该团队在将系统从概念阶段带到临床验证方面做了大量工作。LOBO是一种新一代技术，具有卓越的临床表现，特别适合改变和扩大外周血管疾病患者的治疗。”。

About Okami Medical, Inc.

关于Okami Medical，Inc。

Okami Medical, Inc. is a privately-held medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention. Okami is the second portfolio company of Inceptus Medical LLC, a medical device incubator. Inari Medical, Inc. (NASDAQ: NARI), Inceptus' first portfolio company, is pioneering approaches to treat venous thromboembolism and other diseases.

Okami Medical，Inc.是一家私营医疗器械公司，专注于开发创新解决方案，以解决外周血管介入治疗中未满足的关键临床需求。Okami是医疗器械孵化器Inceptus Medical LLC的第二家投资组合公司。Inceptus的第一家投资组合公司Inari Medical，Inc.（纳斯达克股票代码：NARI）是治疗静脉血栓栓塞和其他疾病的开创性方法。

Okami is backed by members of the board of directors, U.S. Venture Partners (www.usvp.com) and medical device industry veterans. For more information, please visit www.okamimedical.com..

Okami得到了董事会成员、美国风险投资合作伙伴（www.usvp.com）和医疗器械行业资深人士的支持。有关更多信息，请访问www.okamimedical.com。。

Source:Okami Medical, Inc.949-446-9710[email protected]

来源：Okami Medical，Inc.949-446-9710[受电子邮件保护]

SOURCE Okami Medical Inc.

来源Okami Medical Inc。